Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease (Q34112588)

31 July 2017

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease (English)

1 reference

31 July 2017

1 reference

4

Leonard Petrucelli

1 reference

31 July 2017

12

Ted M Dawson

1 reference

31 July 2017

Byoung Dae Lee

1

1 reference

31 July 2017

Joo-Ho Shin

2

1 reference

31 July 2017

Jackalina VanKampen

3

1 reference

31 July 2017

Andrew B West

5

1 reference

31 July 2017

Han Seok Ko

6

1 reference

31 July 2017

Yun-Il Lee

7

1 reference

31 July 2017

Kathleen A Maguire-Zeiss

8

1 reference

31 July 2017

William J Bowers

9

1 reference

31 July 2017

Howard J Federoff

10

1 reference

31 July 2017

Valina L Dawson

11

1 reference

31 July 2017

language of work or name

English

0 references

publication date

22 August 2010

1 reference

31 July 2017

1 reference

31 July 2017

16

1 reference

31 July 2017

9

1 reference

31 July 2017

998-1000

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.2199

31 July 2017

0 references

cites work

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Molecular pathogenesis of Parkinson disease: insights from genetic studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Kinase activity of mutant LRRK2 mediates neuronal toxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

LRRK2 in Parkinson's disease: protein domains and functional insights

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935926

28 October 2018

Identifiers

DOI

10.1038/NM.2199

1 reference

31 July 2017

1 reference

31 July 2017

1 reference